Convalescent plasma, a method of passive immunization that has been applied to prior viral pandemics, holds promise as a potential treatment for COVID. Immunocompromised patients may experience more benefit from convalescent plasma given underlying deficits in B and T cell immunity as well as ...
Purpose:Immunocompromised patients have a potentially increased risk for progression to severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis examined outcomes among immunocompromised participants in the MOVe-OUT trial. Methods:In phase 3 of MOVe-OUT, non-hospitalized at-ris...
Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines. 2022;21(7):877-884.PubMedGoogle ScholarCrossref 19. Senefeld JW, Klassen SA, Ford SK, et al. Use of convalescent plasma in COVID...
9,10,11,12,13 Despite these advances, COVID-19 still results in substantial morbidity in certain patient populations, underscoring the ongoing need for additional therapeutic options, particularly among immunocompromised individuals.14 Adoptive cellular immunotherapy for the treatment of COVID-19 is a ...
The treatment is designed forhigh-risk patientswho have a mild or moderate case of COVID-19 but hope to avoid more severe consequences. You might be considered high-risk if you're: Over 50 Not up to date on COVID vaccinations Immunocompromised ...
A retrospective study was conducted to evaluate the efficacy of high-dose inhaled NO as rescue therapy in COVID-19 patients with respiratory distress. Five patients with severe COVID-19 were enrolled in the study, which was defined by an increased risk of acute hypoxemic respiratory failure with...
The research, published in the PLOS Pathogens journal and released on Tuesday, showed how T cell-based immunotherapy could be utilized in the immunocompromised. "This study gives us hope that we can develop a T cell-based immunotherapy capable of treating multiple COVID-19 variants in the sickes...
Several case reports have demonstrated the efficacy of 3-chymotrypsin-like protease inhibitors in treating prolonged coronavirus disease 2019 (COVID-19) in immunocompromised patients. Tacrolimus (TAC) is a widely used immunosuppressive agent whose blood level can increase significantly due to the ...
Interest in biological therapy for cancer has surged due to its precise targeting of cancer cells and minimized impact on surrounding healthy tissues. This
COVID-19 infection in immunodeficient individuals can result in chronically poor health, persistent or relapsing SARS-CoV-2 PCR positivity, and long-term i